Therapeutic Solutions Receives Allowance on Patent Claim from
the US Patent Office Covering ProJuvenol® Active
Ingredient Pterostilbene in Cancer Immunotherapies
Company Developing Proprietary Nutraceutical ProJuvenol to
Augment FDA Approved Drugs that Help Immune System Fight Cancer
OCEANSIDE, CA -- February 6, 2017 -- InvestorsHub NewsWire --
Therapeutics Solutions International, Inc., (OTC
PINK: TSOI) announced today that the United States Patent
and Trademark Office allowed issuance of a claim covering the
combination of pterostilbene, the active ingredient in its
ProJuvenol® product, together with an FDA-approved
immunotherapeutic drug named Proleukin (aldesleukin) which is a
recombinant form of the cytokine interleukin-2 (IL-2) for treatment
of cancer.
Proleukin® is one of the first immunotherapeutic
drugs approved by the FDA, being indicated for treatment of
metastatic melanoma and metastatic renal cell carcinoma[1]. Scientists
working with Therapeutic Solutions International performed animal
studies showing that administration of pterostilbene increased
efficacy of Proleukin® in melanoma models. In the
studies performed to obtain FDA approval for Proleukin®
responses were seen in 16% of patients[2]. Based on
animal data, it is hoped that the response rate of Proleukin can be
increased by administration of products containing pterostilbene,
such as ProJuvenol®.
"It is important to understand that the immune system does not
work in isolation. The findings by Therapeutic Solutions
International that immune killing of cancer can be augmented by
nutritional modification supports relatively easy to implement
approaches that may have an impact on patient survival" said
Santosh Kesari, MD, Ph.D., member of the Companys Scientific
Advisory Board. Dr. Kesari is also the Chair of Translational
Neurosciences and Neurotherapeutics at the John Wayne Cancer
Institute and the Pacific Neuroscience Institute.
Immuno-Oncology, described by Science Magazine as Breakthrough
of the Year[3] offers the
possibility of not only killing tumor cells in a non-toxic manner,
but also establishing immunological memory, which patrols the body
and destroys recurrent tumor cells. While great progress has been
made in developing drugs that stimulate the immune system to
recognize and kill tumors, a major pitfall of current approaches is
that tumors produce chemicals and oxidative stress that suppresses
the immune system, thus limiting efficacy of immune therapies. The
unique properties of pterostilbene are believed to be useful in
overcoming factors used by the cancer to protect itself from the
immune system. Independent scientific studies have shown that
pterostilbene, which is chemically related to resveratrol, has been
published to possess anticancer[4],[5],
antioxidant[6], and
anti-inflammatory activities[7].
"We are confident that this validation of our science by the
United States Patent and Trademark Office, combined with our
ongoing basic and applied research efforts will help offer patients
non-toxic means of augmenting existing drugs that work by
modulating the immune system" said Timothy Dixon, President and CEO
of Therapeutic Solutions International.
About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
Our new products can be viewed on www.projuvenol.com and products
can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United
States Food and Drug Administration. These products are not
intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
CONTACT INFORMATION
Therapeutic Solutions International, Inc.
ir@tsoimail.com